Related Experiment Video

Updated: May 10, 2026

A Rat Tibial Growth Plate Injury Model to Characterize Repair Mechanisms and Evaluate Growth Plate Regeneration Strategies
06:53

A Rat Tibial Growth Plate Injury Model to Characterize Repair Mechanisms and Evaluate Growth Plate Regeneration Strategies

Published on: July 4, 2017

11.0K

Progress in managing children with achondroplasia

Tashunka Taylor-Miller1, Ravi Savarirayan1,2,3

  • 1Victorian Clinical Genetics Service, Melbourne, Parkville, Victoria, Australia.

Expert Review of Endocrinology & Metabolism
|August 12, 2024
PubMed

Insights

New achondroplasia treatments offer hope for children with this skeletal disorder. Approved therapies like vosoritide and emerging precision medicines aim to improve growth and reduce complications.

Area of Science:

  • Skeletal Dysplasias
  • Pediatric Endocrinology
  • Pharmacology

Background:

  • Achondroplasia is a rare genetic skeletal disorder affecting 300,000 worldwide.
  • Historically, treatment for achondroplasia has been limited to symptom management.
  • Recent advancements have introduced effective therapeutic options for affected children.

Purpose of the Study:

  • To review key therapeutic advances in managing pediatric achondroplasia.
  • To discuss approved and investigational precision therapies.
  • To summarize current clinical trial outcomes for these novel treatments.

Main Methods:

  • Review of current literature on achondroplasia therapeutics.
  • Analysis of clinical trial data for vosoritide, navepegritide, and infigratinib.
  • Discussion of the impact of new therapies on patient outcomes.

Main Results:

  • Vosoritide is the first approved drug for achondroplasia, marking a significant therapeutic shift.
  • Emerging therapies include navepegritide and infigratinib, targeting specific pathways.
  • These treatments aim to alter growth trajectories and decrease medical complications.

Conclusions:

  • The introduction of vosoritide represents a paradigm shift in achondroplasia treatment.
  • Precision therapies hold promise for improving growth, functionality, and reducing complications.
  • Early diagnosis and access to targeted therapies from birth are crucial for optimal outcomes.
Abstract

Keywords:
Achondroplasiafibroblast growth factor receptor 3 (FGFR3)infigratinibnavepegritidevosoritide

More Related Videos

Culturing and Measuring Fetal and Newborn Murine Long Bones06:58

Culturing and Measuring Fetal and Newborn Murine Long Bones

Published on: April 26, 2019

8.2K
Tricolor Transgenic Murine Model for Studying Growth Plate Injury07:58

Tricolor Transgenic Murine Model for Studying Growth Plate Injury

Published on: September 6, 2024

593

Related Concept Videos

Changes in the Appendicular Skeleton with Age01:09

Changes in the Appendicular Skeleton with Age

The upper and lower limb initially develops as a small bulge called a limb bud, which appears on the lateral side of the early embryo. The upper limb bud appears near the end of the fourth week of development, with the lower limb bud appearing shortly after.
Initially, the limb buds consist of a core of mesenchyme covered by a layer of ectoderm. The ectoderm at the end of the limb bud thickens to form a narrow crest called the apical ectodermal ridge. This ridge stimulates the underlying...
Bone Formation by Endochondral Ossification01:24

Bone Formation by Endochondral Ossification

Bone formation, or ossification, begins around the sixth to seventh week of embryonic development. Most bones develop from a cartilaginous template through the process of endochondral ossification. Cartilage formation begins when clusters of mesenchymal cells differentiate into chondrocytes. These chondrocytes proliferate rapidly and secrete an extracellular matrix that becomes encased in a membrane called the perichondrium. The resulting cartilage model provides a template that resembles the...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...